Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Regulatory Filings 2012

Jan 13, 2012

5262_ffr_2012-01-13_a547091e-b12f-43e0-b1a9-71499cb9f64c.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending January 2012

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of an increase in interests in Ordinary shares in GlaxoSmithKline plc purchased at a price of 1445.87 pence per share on 5 January 2012, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 5 January 2012.

Ordinary shares
Dr M M Slaoui 224.551
Mr S M Bicknell 0.099
Mr J M Clarke 583.979
Mr M Dunoyer 98.054
Mr E J Gray 345.334
Mr S A Hussain 217.507
Mr D S Redfern 155.919
Mr J R Stéphenne 239.518
Ms C Thomas 117.867
Mr P C Thomson 82.104
Dr P J T Vallance 99.239

The Company was advised of this information on 13 January 2012.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

13 January 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: January 13, 2012

By: VICTORIA WHYTE


Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc